Elevated serum total IgE - A potential marker for severe chronic urticaria

International Archives of Allergy and Immunology

Volumn 153, Issue 3, 2010, Pages 288-293

  Kessel, Aharon ^a   Helou, Wissam ^a   Bamberger, Ellen ^a   Sabo, Edmond ^a   Nusem, David ^b   Panassof, Josef ^b   Toubi, Elias ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

Author keywords

Autologous serum skin test; Chronic urticaria; IgE levels

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E; THYROID ANTIBODY;

ADULT; ARTICLE; CHRONIC URTICARIA; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAST CELL DEGRANULATION; PRIORITY JOURNAL; SKIN TEST;

ADULT; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN TESTS; URTICARIA;

EID: 77952298581     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314370     Document Type: Article

References (29)

1. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM: BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37: 631-650.
2. Hide M, Francies DM, Grattan CEH, Haki-mi J, Kacham JP, Greave MW: Autoantibod-ies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599-1604.
3. Grattan CE, Francis DM, Hide M, Greave MW: Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695-704.
4. Gruber B, Poznansky M, Boss E, Partin J, Gorevic P, Kaplan AP: Characterization and functional studies of rheumatoid synovial mast cells. Activation by secretagogues, anti-IgE, and a histamine-releasing lymphokine. Arthritis Rheum 1986; 29:944-955.
5. Tong LJ, BalakrishnanG, Kochan JP, Kinet J-P, Kaplan AP: Assessment of autoimmuni-ty in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99: 461-465.
6. Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465-474.
7. Toubi E, Adir-Shani A, Kessel A, Shmuel Z, Sabo E, Hacham H: Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J Clin Immunol 2000; 20: 371-378.
8. Confino-Cohen R, Aharoni D, Goldberg A, Gurevitch I, Buchs A, Weiss M, Weissgarten J, Rapoport MJ: Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 2002; 109: 349-355.
9. Kessel A, Bishara R, Amital A, Bamberger E, Sabo E, Grushko G, Toubi E: Increased plasma levels of matrix MMP-9 are associated with the severity of chronic urticaria. Clin Exp Allergy 2005; 35: 221-225.
10. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, Panasoff J: Clinica l and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59: 869-873.
11. Volonakis M, Katsarou-Katsari A, Stratigos J: Etiologic factors in childhood chronic urticaria. Ann Allergy 1992; 69:61-65.
12. Liutu M, Kalimo K, Uksila J, Kalimo H: Etio-logic aspects of chronic urticaria. Int J Der-matol 1998; 37: 515-519 .
13. Sackesen C, Sekerel BE, Orhan F, Kocabas CN, Tuncer A, Adalioglu G: The etiology of different forms of urticaria in childhood. Pe-diatr Dermatol 2004; 21:102-108.
14. Brunetti L, Francavilla R, Miniello VL, Platzer MH, Rizzi D, Lospalluti ML, Poulsen LK, Armenio L, Skov PS: High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol 2004; 114:922-927.
15. Sabroe RA, Grattan CEI, Francis DM, Barr RM, Black AK, Greaves MW: The autologous serum skin test: a screening test for autoan-tibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140:446-452.
16. Pepys J: Skin tests for immediate, type I allergic reactions. Proc R Soc Med 1972; 65: 271-272.
17. Breneman D, Bronsky AK, Bruce S: Cetiri-zine and astemisone therapy for chronic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol 1995; 33: 192-198.
18. Hetman S, Kivity S, Greif J, Fireman EM, Topilsky M: IgE values in the allergic and healthy Israeli population. Ann Allergy 1988; 61:123-128.
19. Droste JH, Kerhof M, De Monchy JG, Schouten JP, Rijcken B: Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study. The Dutch ECRHS Group. J Allergy Clin Immunol 1996; 97:922-932.
20. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C: The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115:459-465.
21. Spector SL, Tan RA: Effects of omalizumab on patients with chronic urticaria. Ann Al-lerg y Asthma Immunol 2007; 99: 190-193.
22. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK: Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569-573.
23. Sands MF, Blume JW, Schwartz SA: Successful treatment of 3patients with recurrent id-iopathic angioedema with omalizumab. J Allergy Clin Immunol 2007; 120:979-981.
24. Dreyfus DH: Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Ann Allergy Asthma Immunol 2008; 10 0: 624-625.
25. Godse KV: Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol 2008; 74: 157-158.
26. Kawakami T, Kitaura J: Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance. J Immunol 2005; 175: 4167-4173.
27. Kitaura J, Eto K, Kinoshita T, Kawakami Y, Leitges M, Lowell CA, Kawakami T: Regulation of highly cytokinergic IgE-induced mast cell adhesion by Src, Syk, Tec, and protein kinase C family kinases. J Immunol 2005; 174:4495-4504.
28. Kashiwakura JI, Xiao W, Kitaura J, Kawaka-m i Y, M aeda-Ya m a mot o M, P fe i f fer J R , Wi l-son BS, Blank U, Kawakami T: Pivotal advance: IgE accelerates in vitro development of mast cells and modifies their phenotype. J Leukoc Biol 2008; 84:357-367.
29. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB: Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:1147-1154.